Assessing the Burden of Respiratory Syncytial Virus (RSV)
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Respiratory Syncytial Virus (RSV) Infection, Acute Lower Respiratory Tract Infections, Bronchiolitis, Pneumonia. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Arab Emirates
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Assessing the Burden of Respiratory Syncytial Virus (RSV): the Assessment of the Burden of Respiratory Syncytial Virus (RSV) Across Different Age Groups and Risk Factors
Overview
This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand: * How often does RSV occur * Who is most at risk * The long-term and financial effects of RSV
Detailed description
This study is designed to analyze the impact of Respiratory Syncytial Virus (RSV) across different age groups. It focuses on how often RSV occurs, who is most at risk, and its long-term and financial effects. The study uses existing hospital records from SEHA facilities between January 2018 and December 2024. This is a retrospective observational study, meaning no new tests or treatments are given. Researchers look at medical records from past patients who were diagnosed with RSV. Anonymized data is collected from SEHA's Electronic Medical Records (EMR) and laboratory systems. Only patients with confirmed RSV infections are included.
Primary outcome measures
- Burden of RSV Infection Across All Age Groups [Time frame: January 2018 - December 2024]
- Burden of RSV Infection Across All Age Groups [Time frame: January 2018 - December 2024]
Secondary outcome measures (7)
- Identification of Risk Factors for Severe RSV Infection [Time frame: January 2018 - December 2024]
- Proportion of Hospital Admissions Due to RSV [Time frame: January 2018 - December 2024]
- ICU Admission Rates for RSV-Infected Patients [Time frame: January 2018 - December 2024]
- Financial Burden of RSV Infection [Time frame: January 2018 - December 2024]
- Incidence of Recurrent Wheezing and Asthma Diagnosis Following RSV Infection [Time frame: Up to 12 months post-infection]
- RSV-Associated Mortality Rates [Time frame: January 2018 - December 2024]
- Long-Term Respiratory Outcomes Following RSV Infection [Time frame: Up to 12 months post-infection]
Eligibility criteria
Inclusion criteria
- Patients of all ages with a confirmed diagnosis of RSV infection
- Patients admitted to a SEHA hospital or healthcare facility between January 2018 and December 2024
- Patients with documented data in the SEHA electronic medical record (EMR) system
Exclusion criteria
- Patients with suspected RSV infection that is not laboratory-confirmed
- Patients without sufficient data in the SEHA EMR system
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United Arab Emirates · 1 center
- Sheikh Khalifa Medical City (Abu Dhabi Health Research Centre), SEHA — Abu Dhabi
Publications
- Felton DA. A time of 'firsts'. J Prosthodont. 2004 Mar;13(1):1-2. doi: 10.1111/j.1532-849X.2004.04011.x. No abstract available. PMID 15032890
- Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012 May;54(10):1427-36. doi: 10.1093/cid/cis211. Epub 2012 Apr 10. PMID 22495079
- Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009 Feb 5;360(6):588-98. doi: 10.1056/NEJMoa0804877. PMID 19196675
- Wassmer SC, Lepolard C, Traore B, Pouvelle B, Gysin J, Grau GE. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J Infect Dis. 2004 Jan 15;189(2):180-9. doi: 10.1086/380761. Epub 2004 Jan 9. PMID 14722881
- Callen A, Diener-West M, Zeitlin PL, Rubenstein RC. A simplified cyclic adenosine monophosphate-mediated sweat rate test for quantitative measure of cystic fibrosis transmembrane regulator (CFTR) function. J Pediatr. 2000 Dec;137(6):849-55. doi: 10.1067/mpd.2000.109198. PMID 11113843
- Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951. PMID 15858184
- Joury J, Al Kaabi N, Al Dallal S, Mahboub B, Zayed M, Abdelaziz M, Onwumeh-Okwundu J, Fletcher MA, Kumaresan S, Ramachandrachar BC, Farghaly M. Retrospective Analysis of RSV Infection in Pediatric Patients: Epidemiology, Comorbidities, Treatment, and Costs in Dubai (2014-2023). J Health Econ Outcomes Res. 2024 Nov 5;11(2):133-144. doi: 10.36469/001c.123889. eCollection 2024. PMID 39575134
- Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 Ma PMID 20399493
Identifiers
NCT: NCT07015255 · DOH/ADHRTC/2025/361